PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:

Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
European Inter-Institutional Impact Study of MammaPrint
PUBLICATION: The Breast August 2014, Volume 23, Issue 4, Pages 423โ428 AUTHORS: P.G. Cusumano, D. Generali, E. Ciruelos, L. Manso, I. Ghanem, E. Lifrange, G. Jerusalem, J. Klaase, F. de Snoo, L. Stork-Sloots, L. Dekker-Vroling, M. Lutke Holzik SUMMARY: Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancer patients was Read More
Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms
PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub 2014 Apr 24. AUTHORS: C.A. Drukker, M.V. Nijenhuis, J.M. Bueno-de-Mesquita, V.P. Retรจl, W.H. van Harten, H. van Tinteren, J. Wesseling, M.K. Schmidt, L.J. vanโt Veer, G.S. Sonke, E.J. T. Rutgers, M.J. van de Vijver, S.C. Linn SUMMARY: In this cohort, Read More
Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature
PUBLICATION: Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Feb 13. AUTHORS: Drukker C.A., van den Hout H.C., Sonke G.S., Brain E., Bonnefoi H., Cardoso F., Goldhirsch A., Harbeck N., Honkoop A.H., Koornstra R.H., van Laarhoven H.W., Portielje J.E., Schneeweiss A., Smorenburg C.H., Stouthard J., Linn S.C., Schmidt M.K. Read More
MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue
PUBLICATION: J Mol Diagn. 2014 Mar;16(2):190-7. doi: 10.1016/j.jmoldx.2013.10.008. Epub 2013 Dec 28. AUTHORS: Anna Sapino, Paul Roepman, Sabine C. Linn, Mireille H.J. Snel, Leonie J.M.J. Delahaye, Jeroen van den Akker, Annuska M. Glas, Iris M. Simon, Neil Barth, Femke A. de Snoo, Laura J. van โt Veer, Luca Molinaro, Els Read More
Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers
PUBLICATION: Breast Cancer Res Treat. 2014 Feb;144(1):103-11. doi: 10.1007/s10549-013-2830-5. Epub 2014 Jan 28.7 AUTHORS: Drukker C.A., Schmidt M.K., Rutgers E.J., Cardoso F., Kerlikowske K., Esserman L.J., van Leeuwen F.E., Pijnappel R.M., Slaets L., Bogaerts J., Van't Veer L.J. SUMMARY: Among the screen-detected cancers, 32 % had a 70-gene signature high-risk Read More
Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome
PUBLICATION: Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21. AUTHORS: Drukker C.A., van Tinteren H., Schmidt M.K., Rutgers E.J., Bernards R., van de Vijver M.J., Van't Veer L.J. SUMMARY: MammaPrint showed a significant absolute difference in DMFS and OS at 25 years between the patients with Read More
Prospective Cost-Effectiveness Analysis of Genomic Profiling in Breast Cancer
PUBLICATION: European Journal of Cancer. December 2013, Volume 49, Issue 18, Pages 3773โ3779 AUTHORS: V.P. Retรจl, M.A. Jooreb, C.A. Drukker, J.M. Bueno-de-Mesquita, M. Knauer, H. van Tinteren, S.C. Linn, W.H. van Harten SUMMARY: The total health care costs per patient were โฌ26,786 for the 70-gene and โฌ29,187 for AO. The Read More